The effect of sulindac, a non-steroidal anti-inflammatory drug, attenuates inflammation and fibrosis in a mouse model of chronic pancreatitis

BMC Gastroenterology

Xiaoguang Dou²  Lin Zhang²  Xiaokai Chen¹  Han Bai² 

[1] Department of Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China;Department of Infectious Disease, Shengjing Hospital of China Medical University, Shenyang, 110004, China

关键词: Chemoprevention;    Chronic pancreatitis;    Sulindac;   

Others  :  1088686
DOI  :  10.1186/1471-230X-12-115

 received in 2012-03-30, accepted in 2012-08-02,  发布年份 2012

【 摘 要 】

Background

Chronic pancreatitis is characterized by progressive fibrosis, pain and loss of exocrine and endocrine functions. The long-standing chronic pancreatitis and its associated pancreatic fibrosis are the most common pathogenic events involved in human pancreatic carcinogenesis, but the therapeutic strategies to chronic pancreatitis and the chemoprevention of pancreatic carcinogenesis are very limited.

Methods

We investigated the effect of sulindac, a non-steroidal anti-inflammatory drug (NSAID), on inhibition of chronic pancreatitis in a caerulein induced chronic pancreatitis mouse model.

Results

Sulindac significantly reduced the severity of chronic pancreatitis including the extent of acini loss, inflammatory cell infiltration and stromal fibrosis. The protein expression of phosphorylation of MEK/ERK was inhibited in the chronic pancreatic tissues by sulindac treatment as measured by Western blot assay. The levels of inflammatory cytokines including TNF-α and MCP-1 were also significantly decreased with sulindac treatment, as well as the expression of TGF-β, PDGF-β, SHH and Gli in the chronic pancreatic tissue detected by qPCR assay and confirmed by western blot assay. The activation of pancreatic satellet cells was also inhibited by sulindac as measured by the activity of α-smooth muscle actin (α-SMA) in the pancreatic tissue of chronic pancreatitis.

Conclusions

Sulindac is a promising reagent for the treatment of chronic pancreatitis via inhibition of inflammatory cell infiltration and stromal fibrosis, the inhibitory effect of sulindac on chronic pancreatitis may through targeting the activation ERK/MAPK signaling pathway.

【 授权许可】

   
2012 Bai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Reding T, et al.: A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. Gut 2006, 55(8):1165-1173.
• [2]Ulmasov B, et al.: Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. Am J Physiol Gastrointest Liver Physiol 2010, 299(1):G70-G80.
• [3]Shimizu K: Mechanisms of pancreatic fibrosis and applications to the treatment of chronic pancreatitis. J Gastroenterol 2008, 43(11):823-832.
• [4]Charrier AL, Brigstock DR: Connective tissue growth factor production by activated pancreatic stellate cells in mouse alcoholic chronic pancreatitis. Lab Invest 2010, 90(8):1179-1188.
• [5]Phillips PA, et al.: Cell migration: a novel aspect of pancreatic stellate cell biology. Gut 2003, 52(5):677-682.
• [6]Mews P, et al.: Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut 2002, 50(4):535-541.
• [7]Talukdar R, Tandon RK: Pancreatic stellate cells: new target in the treatment of chronic pancreatitis. J Gastroenterol Hepatol 2008, 23(1):34-41.
• [8]Yang L, et al.: L-cysteine administration attenuates pancreatic fibrosis induced by TNBS in rats by inhibiting the activation of pancreatic stellate cell. PLoS One 2012, 7(2):e31807.
• [9]Kayed H, et al.: Distribution of Indian hedgehog and its receptors patched and smoothened in human chronic pancreatitis. J Endocrinol 2003, 178(3):467-478.
• [10]Shinozaki S, et al.: Indian hedgehog promotes the migration of rat activated pancreatic stellate cells by increasing membrane type-1 matrix metalloproteinase on the plasma membrane. J Cell Physiol 2008, 216(1):38-46.
• [11]Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.
• [12]Schlosser W, et al.: Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 2002, 25(1):26-30.
• [13]Silva A, et al.: COX-2 is not required for the development of murine chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol 2011, 300(6):G968-G975.
• [14]Polito F, et al.: Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis. Br J Pharmacol 2010, 161(5):1002-1011.
• [15]Marshall TM, et al.: Activation of descending pain-facilitatory pathways from the rostral ventromedial medulla by cholecystokinin elicits release of prostaglandin-E(2) in the spinal cord. Pain 2012, 153(1):86-94.
• [16]Masuko K, et al.: Prostaglandin E2 regulates the expression of connective tissue growth factor (CTGF/CCN2) in human osteoarthritic chondrocytes via the EP4 receptor. BMC Res Notes 2010, 3:5. BioMed Central Full Text
• [17]Chan MM, Moore AR: Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J Immunol 2010, 184(11):6418-6426.
• [18]Roberts HR, et al.: Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation. Carcinogenesis 2011, 32(11):1741-1747.
• [19]Hasan S, et al.: Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas 2008, 37(2):121-127.
• [20]Aoki H, et al.: Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. Am J Physiol Cell Physiol 2007, 292(1):C259-C268.
• [21]Seo SW, et al.: Selective cyclooxygenase-2 inhibitor ameliorates cholecystokinin-octapeptide-induced acute pancreatitis in rats. World J Gastroenterol 2007, 13(16):2298-2304.
• [22]Haanen C: Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs 2001, 2(5):677-683.
• [23]Willemer S, Elsasser HP, Adler G: Hormone-induced pancreatitis. Eur Surg Res 1992, 24(Suppl 1):29-39.
• [24]Yoo BM, et al.: Novel antioxidant ameliorates the fibrosis and inflammation of cerulein-induced chronic pancreatitis in a mouse model. Pancreatology 2005, 5(2–3):165-176.
• [25]Aghdassi AA, et al.: Animal models for investigating chronic pancreatitis. Fibrogenesis Tissue Repair 2011, 4(1):26. BioMed Central Full Text
• [26]Neuschwander-Tetri BA, et al.: Repetitive self-limited acute pancreatitis induces pancreatic fibrogenesis in the mouse. Dig Dis Sci 2000, 45(4):665-674.
• [27]Su KH, Cuthbertson C, Christophi C: Review of experimental animal models of acute pancreatitis. HPB (Oxford) 2006, 8(4):264-286.
• [28]Mahmoud NN, et al.: The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998, 19(1):87-91.
• [29]Bai H, et al.: Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice. Carcinogenesis 2011, 32(11):1689-1696.
• [30]Seril DN, et al.: Inhibition of chronic ulcerative colitis-associated colorectal adenocarcinoma development in a murine model by N-acetylcysteine. Carcinogenesis 2002, 23(6):993-1001.
• [31]Tandon RK, Garg PK: Oxidative stress in chronic pancreatitis: pathophysiological relevance and management. Antioxid Redox Signal 2011, 15(10):2757-2766.
• [32]van Westerloo DJ, et al.: Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J Pathol 2005, 166(3):721-728.
• [33]Wang X, Lin Y: Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 2008, 29(11):1275-1288.
• [34]Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5(10):749-759.
• [35]Grivennikov SI, Karin M: Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010, 20(1):65-71.
• [36]Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
• [37]Carr MW, et al.: Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 1994, 91(9):3652-3656.
• [38]Masamune A, et al.: Differential roles of signaling pathways for proliferation and migration of rat pancreatic stellate cells. Tohoku J Exp Med 2003, 199(2):69-84.